Recurrence and mortality after first venous thromboembolism in a large population-based cohort

被引:66
作者
Arshad, N. [1 ]
Bjori, E. [1 ]
Hindberg, K. [1 ]
Isaksen, T. [1 ,2 ]
Hansen, J. -B. [1 ,2 ]
Braekkan, S. K. [1 ,2 ]
机构
[1] UiT Arctic Univ Norway, Dept Clin Med, KG Jebsen Thrombosis Res & Expertise Ctr TREC, N-9037 Tromso, Norway
[2] Univ Hosp North Norway, Div Internal Med, Tromso, Norway
关键词
cancer; epidemiology; mortality; recurrence; venous thromboembolism; DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; PREDICTIVE FACTOR; CLINICAL-COURSE; WORCESTER VTE; RISK; OUTCOMES; TRENDS; MEN; EPIDEMIOLOGY;
D O I
10.1111/jth.13587
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Previous reports on recurrence and mortality rates after a first episode of venous thromboembolism (VTE) vary considerably. Advances in the management and treatment of VTE during the last 15 years may have influenced the rates of clinical outcomes. Aim: To estimate the rates of recurrence and mortality after a first VTE in patients recruited from a large population-based cohort. Method: From the Tromso study, patients (n = 710) with a first, symptomatic, objectively confirmed VTE were included and followed in the period 1994-2012. Recurrent episodes of VTE were identified from multiple sources and carefully validated by review of medical records. Incidence rates and cumulative incidence rates with 95% confidence intervals (CIs) of VTE recurrence and mortality were calculated. Results: The mean age of the patients was 68 years (range 28-102 years), and 166 (23.4%) had cancer at the time of first VTE. There were 114 VTE recurrences and 333 deaths during a median study period of 7.7 years (range 0.04-18.2 years). The risk of recurrence was highest during the first year. The overall 1-year recurrence rate was 7.8 (95% CI 5.8-10.6) per 100 person-years (PY), whereas the recurrence rate in the remaining follow-up period (1-18 years) was 3.0 (95% CI 2.4-3.8) per 100 PY. The overall 1-year all-cause mortality rate was 29.9 (95% CI 25.7-34.8) per 100 PY, and in those without cancer the corresponding rate was 23.6 (95% CI 17.8-31.3) per 100 PY. Conclusion: Despite advances in VTE management, the rates of adverse events remained fairly high, particularly in the first year following a first VTE.
引用
收藏
页码:295 / 303
页数:9
相关论文
共 40 条
[21]   Competing Risk Regression Models for Epidemiologic Data [J].
Lau, Bryan ;
Cole, Stephen R. ;
Gange, Stephen J. .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 170 (02) :244-256
[22]   A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis [J].
Levine, M ;
Gent, M ;
Hirsh, J ;
Leclerc, J ;
Anderson, D ;
Weitz, J ;
Ginsberg, J ;
Turpie, AG ;
Demers, C ;
Kovacs, M ;
Geerts, W ;
Kassis, J ;
Desjardins, L ;
Cusson, J ;
Cruickshank, M ;
Powers, P ;
Brien, W ;
Haley, S ;
Willan, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11) :677-681
[23]   Incidence and mortality of venous thrombosis:: a population-based study [J].
Naess, I. A. ;
Christiansen, S. C. ;
Romundstad, P. ;
Cannegieter, S. C. ;
Rosendaal, F. R. ;
Hammerstrom, J. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (04) :692-699
[24]   A PROSPECTIVE-STUDY OF THE INCIDENCE OF DEEP-VEIN THROMBOSIS WITHIN A DEFINED URBAN-POPULATION [J].
NORDSTROM, M ;
LINDBLAD, B ;
BERGQVIST, D ;
KJELLSTROM, T .
JOURNAL OF INTERNAL MEDICINE, 1992, 232 (02) :155-160
[25]   Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism [J].
Prandoni, P ;
Lensing, AWA ;
Prins, MH ;
Bernardi, E ;
Marchiori, A ;
Bagatella, P ;
Frulla, M ;
Mosena, L ;
Tormene, D ;
Piccioli, A ;
Simioni, P ;
Girolami, A .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (12) :955-960
[26]   The long-term clinical course of acute deep venous thrombosis [J].
Prandoni, P ;
Lensing, AWA ;
Cogo, A ;
Cuppini, S ;
Villalta, S ;
Carta, M ;
Cattelan, AM ;
Polistena, P ;
Bernardi, E ;
Prins, MH .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (01) :1-+
[27]   The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients [J].
Prandoni, Paolo ;
Noventa, Franco ;
Ghirarduzzi, Angelo ;
Pengo, Vittorio ;
Bernardi, Enrico ;
Pesavento, Raffaele ;
Iotti, Matteo ;
Tormene, Daniela ;
Simioni, Paolo ;
Pagnan, Antonio .
HAEMATOLOGICA, 2007, 92 (02) :199-205
[28]   Thrombosis A Major Contributor to Global Disease Burden [J].
Raskob, G. E. ;
Angchaisuksiri, P. ;
Blanco, A. N. ;
Buller, H. ;
Gallus, A. ;
Hunt, B. J. ;
Hylek, E. M. ;
Kakkar, A. ;
Konstantinides, S. V. ;
McCumber, M. ;
Ozaki, Y. ;
Wendelboe, A. ;
Weitz, J. I. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34 (11) :2363-2371
[29]   Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment [J].
Roach, R. E. J. ;
Cannegieter, S. C. ;
Lijfering, W. M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (10) :1593-1600
[30]   A COMPARISON OF 6 WEEKS WITH 6 MONTHS OF ORAL ANTICOAGULANT-THERAPY AFTER A FIRST EPISODE OF VENOUS THROMBOEMBOLISM [J].
SCHULMAN, S ;
RHEDIN, AS ;
LINDMARKER, P ;
CARLSSON, A ;
LARFARS, G ;
NICOL, P ;
LOOGNA, E ;
SVENSSON, E ;
LJUNGBERG, B ;
WALTER, H ;
VIERING, S ;
NORDLANDER, S ;
LEIJD, B ;
JONSSON, KA ;
HJORTH, M ;
LINDER, O ;
BOBERG, J ;
GUSTAFSSON, C ;
GRONDAHL, A ;
TORNEBOHM, E ;
JOHANSSON, M ;
LOCKNER, D ;
JOHNSSON, H ;
KOBOSKO, J ;
MALMROS, B ;
ARCINI, N ;
SAAW, J ;
STIG, R ;
WILHELMSSON, S ;
OHLSSON, A ;
MALMQVIST, K ;
ALKHALILI, F ;
PETRESCU, A ;
BROHULT, J ;
HULTING, J ;
EKLUND, SG ;
DAHLIN, L ;
MARJANOVICS, B ;
MALM, C ;
LINDGREN, A ;
FAGRELL, B ;
KALLNER, M ;
GRANQVIST, S ;
WIMAN, B ;
EGBERG, N ;
WADMAN, B ;
SNYDER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (25) :1661-1665